WallStSmart

Amrize Ltd (AMRZ)vsCementos Pacasmayo SAA ADR (CPAC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Amrize Ltd generates 458% more annual revenue ($11.81B vs $2.12B). AMRZ leads profitability with a 10.0% profit margin vs 7.3%. CPAC appears more attractively valued with a PEG of 1.13. AMRZ earns a higher WallStSmart Score of 55/100 (C-).

AMRZ

Buy

55

out of 100

Grade: C-

Growth: 3.3Profit: 6.5Value: 7.3Quality: 5.8
Piotroski: 3/9

CPAC

Buy

54

out of 100

Grade: C-

Growth: 4.7Profit: 5.5Value: 9.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.58
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMRZSignificantly Overvalued (-119.3%)

Margin of Safety

-119.3%

Fair Value

$26.88

Current Price

$56.12

$29.24 premium

UndervaluedFair: $26.88Overvalued
CPACUndervalued (+29.4%)

Margin of Safety

+29.4%

Fair Value

$15.43

Current Price

$10.20

$5.23 discount

UndervaluedFair: $15.43Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMRZ2 strengths · Avg: 8.0/10
Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$1.65B8/10

Generating 1.6B in free cash flow

CPAC0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

AMRZ4 concerns · Avg: 3.3/10
P/E RatioValuation
25.9x4/10

Moderate valuation

EPS GrowthGrowth
3.6%4/10

3.6% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Revenue GrowthGrowth
-0.4%2/10

Revenue declined 0.4%

CPAC4 concerns · Avg: 3.5/10
Price/BookValuation
12.9x4/10

Trading at 12.9x book value

Altman Z-ScoreHealth
1.584/10

Distress zone — elevated risk

Market CapQuality
$809.12M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
7.3%3/10

7.3% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : AMRZ

The strongest argument for AMRZ centers on Price/Book, Free Cash Flow. PEG of 1.40 suggests the stock is reasonably priced for its growth.

Bull Case : CPAC

PEG of 1.13 suggests the stock is reasonably priced for its growth.

Bear Case : AMRZ

The primary concerns for AMRZ are P/E Ratio, EPS Growth, Piotroski F-Score.

Bear Case : CPAC

The primary concerns for CPAC are Price/Book, Altman Z-Score, Market Cap.

Key Dynamics to Monitor

CPAC is growing revenue faster at 6.2% — sustainability is the question.

AMRZ generates stronger free cash flow (1.6B), providing more financial flexibility.

Monitor BUILDING MATERIALS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AMRZ scores higher overall (55/100 vs 54/100). CPAC offers better value entry with a 29.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amrize Ltd

BASIC MATERIALS · BUILDING MATERIALS · USA

Amrize Ltd (AMRZ) is an innovative technology company at the forefront of the digital health and wellness sector, striving to transform healthcare delivery through advanced technologies and data-driven solutions. With a strong emphasis on enhancing patient outcomes and increasing healthcare accessibility, Amrize engages in extensive research and development to address the growing demand for scalable health solutions. The company’s strategic initiatives position it to play a pivotal role in the evolving landscape of healthcare, making it a critical player in the advancement of modern healthcare systems.

Visit Website →

Cementos Pacasmayo SAA ADR

BASIC MATERIALS · BUILDING MATERIALS · USA

Cementos Pacasmayo SAA, a cement company, produces, distributes and sells cement and cement-related materials in Peru. The company is headquartered in Lima, Peru.

Want to dig deeper into these stocks?